医学
肿瘤科
围手术期
免疫疗法
内科学
新辅助治疗
病态的
完全响应
肝细胞癌
不利影响
临床研究阶段
肿瘤微环境
索拉非尼
临床试验
毒性
实体瘤疗效评价标准
放射科
联合疗法
总体生存率
生物标志物
靶向治疗
伦瓦提尼
外科
肾细胞癌
危险分层
作者
Lu Chen,Ruyu Han,Shujie Zhai,Yimeng Wang,Xiaochen Ma,Zhizhuo Cao,Guangtao Li,Shaojun Zhang,Wenchen Gong,Jihui Hao,Tianqiang Song
标识
DOI:10.1016/j.drup.2026.101440
摘要
AIMS: It is controversial whether monotherapy with immunotherapeutics is effective in early-stage hepatocellular carcinoma (HCC). We evaluated immunotherapy monotherapy as an initial neoadjuvant strategy. METHODS: This prospective, single-arm, phase II trial of an adaptive neoadjuvant strategy enrolled patients with resectable, early-stage HCC. All patients received tislelizumab monotherapy; non-responders received subsequent lenvatinib combination therapy preoperatively. RESULTS: For the overall efficacy of all 36 patients, the objective response rates were 13.9% and 30.6% as per the Response Evaluation Criteria in Solid Tumours v1.1 and modified Response Evaluation Criteria in Solid Tumours, respectively. Among the 33 patients who underwent resection, the major pathological response rate was 33.3% and the pathological complete response rate was 15.2%. Overall, grade ≥ 3 treatment-emergent adverse events occurred in 11.1%, with no surgical delays. Monotherapy responses were predicted by pretreatment tumour microenvironment features. Immune-regulatory cancer-associated fibroblasts colocalized with T cells identified responders, whereas angiogenic-metabolic signatures predicted resistance. A multimodal model integrating blood-based and imaging biomarkers accurately identified monotherapy-sensitive patients (average precision, 0.9167). The specificity for identifying responders was 100%. CONCLUSIONS: These preliminary findings suggest that neoadjuvant immunotherapy monotherapy exhibits promising antitumour activity and demonstrates a manageable safety profile in early-stage HCC. The tailored stratification approach appears clinically feasible and may help minimize unnecessary exposure to combination therapy-related toxicity while retaining tentative therapeutic efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI